CLINICAL_TRIALS ClinicalTrials.gov record update

Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies (PIVOT IO 020)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04730349
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:15.145527+00:00
Published At: 2023-03-24T00:00:00+00:00
Record Updated At: 2023-03-24
Results Posted At: 2023-03-24
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Ependymoma", "Ewing Sarcoma", "High-grade Glioma", "Leukemia and Lymphoma", "Medulloblastoma", "Miscellaneous Brain Tumors", "Miscellaneous Solid Tumors", "Neuroblastoma", "Relapsed, Refractory Malignant Neoplasms", "Rhabdomyosarcoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-03-24"
protocolSection.identificationModule.nctId: "NCT04730349"
protocolSection.identificationModule.officialTitle: "Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies (PIVOT IO 020)"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2023-03-24"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.